Merck scores FDA approval for subcutaneous Keytruda, securing potential blockbuster protection

Merck has secured FDA approval for Keytruda Qlex, a subcutaneous formulation of its blockbuster cancer drug, for all existing solid tumor indications. This approval is a critical strategic move to protect Keytruda's substantial revenue stream—which generated $8 billion in Q2 2023—ahead of the intravenous version's patent expiration in 2028, offering patients significantly reduced treatment times while demonstrating comparable efficacy. The company aims to transition 30-40% of Keytruda users to the new formulation within 18-24 months, a key component of Merck's strategy to maintain top-line stability and mitigate revenue erosion, despite ongoing patent litigation concerning the subcutaneous delivery technology.

Analysis

The FDA's approval of Keytruda Qlex, a subcutaneous formulation of Merck's flagship oncology drug, represents a critical execution of the company's life-cycle management strategy. This approval is pivotal for defending the franchise's revenue, which accounted for over half of Merck's total sales with $8 billion in the second quarter, ahead of the intravenous version's patent expiration in 2028. The new formulation demonstrates comparable efficacy to the original, based on pharmacokinetic and clinical outcome data from the MK-3475A-D77 study, but offers a significant reduction in administration time from over 30 minutes to approximately one or two minutes. This convenience factor is expected to be a primary driver of adoption, with Merck targeting a 30% to 40% conversion of its Keytruda user base within the next 18 to 24 months. However, a material risk overhangs this strategic win in the form of ongoing patent litigation with Halozyme Therapeutics concerning the subcutaneous delivery technology. While the approval allows Merck to proceed with the launch and compete with existing subcutaneous immunotherapies from Bristol Myers Squibb and Roche, an unfavorable legal outcome could impose significant royalty costs or other penalties, impacting the drug's long-term profitability. This development must be viewed in the context of Merck's broader corporate actions, including a major cost-cutting initiative to save $3 billion annually, highlighting the immense pressure on the Keytruda franchise to mitigate the impending patent cliff and stabilize the company's top line.

Key Decisions for Investors

• Investors in Merck (MRK) should view this approval as a significant de-risking event for the 2028 patent cliff, and should monitor the adoption rate of Keytruda Qlex against the company's 30-40% target as a key performance indicator.
• The ongoing patent litigation with Halozyme Therapeutics (HALO) is a key risk factor that could materially affect the profitability of Keytruda Qlex; the outcome of this legal dispute warrants close monitoring.
• While this approval strengthens Merck's competitive positioning, its ultimate success is crucial given the company's heavy reliance on the Keytruda franchise and recent restructuring efforts, making the execution of this product switch a central element of the investment thesis.
• Consider that while Keytruda Qlex offers a best-in-class administration time, the market for subcutaneous PD-1 inhibitors already includes competitors like Bristol Myers Squibb (BMY), meaning market share gains are not guaranteed and will be hard-fought.